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Purpose: Amifampridine (3,4-diaminopyridine) has
been approved in the European Union for the treatment
of Lambert-Eaton myasthenic syndrome. Amifampridine
has a narrow therapeutic index, and supratherapeutic
exposure has been associated with dose-dependent ad-
verse events, including an increased risk for seizure. This
study assessed the effect of food on the relative bioavail-
ability of amifampridine in healthy subjects and informed
on conditions that can alter exposure.
Methods: This randomized, open-labeled, 2-treat-
ment, 2-period crossover study enrolled 47 healthy
male and female subjects. Subjects were randomly
assigned to receive 2 single oral doses of amifampri-
dine phosphate salt (20 mg base equivalents per dose)
under fed or fasted conditions separated by a washout
period. Blood and urine samples for pharmacokinetic
analyses were taken before and after dosing. Plasma
concentrations of amifampridine and an inactive 3-N-
acetyl metabolite were determined. The relative bio-
availability values of amifampridine and metabolite
were assessed based on the plasma PK parameters
AUC0–1, AUC0–t, and Cmax in the fed and fasted
states using noncompartmental pharmacokinetic anal-
ysis. Parent drug and metabolite excretion were
calculated from urinary concentrations. A food effect
on bioavailability would be established if the 90% CI
of the ratio of population geometric mean value of
AUC0–1, AUC0–t, or Cmax between fed and fasted
administration was not within the bioequivalence
range of 80% to 125%. Tolerability was assessed
based on adverse-event reporting, clinical laboratory
assessments, physical examination including vital sign
measurements, 12-lead ECG, and concurrent medica-
tion use.
Findings: Food slowed and somewhat decreased the
absorption of amifampridine. There was a decrease in
exposure (Cmax, 44%; AUC, 20%) after oral admin-
istration of amifampridine phosphate salt in the
presence of food, and mean Tmax was 2-fold longerJuly 2015in the fed state. The extent of exposure and plasma
elimination half-life of the major metabolite was
greater than those of amifampridine in the fed and
fasted conditions. Mean AUCs in the fed and fasted
states were slightly greater in women than men, with
no difference in mean Cmax. Orally administered
amifampridine was renally eliminated (493%) as
the parent compound and metabolite within 24 hours.
Single oral doses of 20 mg of amifampridine phos-
phate salt were considered well tolerated in both the
fed and fasted conditions. High intersubject variability
(%CVs, 430%) in amifampridine pharmacokinetic
parameter values was observed.
Implications: At the intended dose under fasting
conditions, amifampridine exposure may be increased.
European Union Drug Regulating Authorities Clinical
Trials identiﬁer: 2011-000596-13. (Clin Ther. 2015;
37:1555–1563) & 2015 The Authors. Published by
Elsevier HS Journals, Inc.
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3,4-Diaminopyridine (3,4-DAP) has been used for
425 years for treating a variety of neurologic disor-
ders of axonal or synaptic transmission, including
Lambert-Eaton myasthenic syndrome (LEMS),1,2
myasthenia gravis, congenital myasthenia, multiple
sclerosis, and downbeat nystagmus.3–5 3,4-DAP blocks
voltage-dependent potassium ion channels, thereby
prolonging the action potential and presynaptic cell1555
Clinical Therapeuticsmembrane depolarization, enhancing inﬂux or trans-
port of calcium into the nerve ending. The resulting
increase in intracellular calcium concentration facili-
tates exocytosis of acetylcholine-containing vesicles,
leading to an increased concentration of acetylcholine
at the motor end plate,6 which in turn results in
improved neuromuscular transmission and
augmented muscle contraction and strength.7,8
Over the past 25 years, a considerable amount of
clinical experience with 3,4-DAP has been gained, pro-
viding a strong body of evidence supporting its efﬁcacy
and tolerability in the treatment of patients with LEMS.1,2
3,4-DAP is a standard of care for LEMS in the United
States and has been recommended by the European
Academy of Neurology (formerly, European Federation
of Neurological Societies) for ﬁrst-line symptomatic treat-
ment of patients with LEMS.9 For many years, the
absence of a product approved for the treatment of this
condition led physicians to prescribe ad hoc preparations
of amifampridine base from compounding pharmacies or
independent small-scale manufacturers. The process of
producing these products was associated with consider-
able batch variability, lack of reliability in drug quality,
safety concerns for the people manipulating the free base,
and a risk for overdose due to compounding errors.10
A new oral phosphate salt formulation of 3,4-DAP
(amifampridine) was approved by the European Med-
icines Agency in 2009.11 Comparability of the base
versus the phosphate salt formulation of 3,4-DAP was
demonstrated in a previously conducted double-blind,
single-dose, crossover, bioavailability/bioequivalence
study conducted in 27 healthy male subjects.2 The
pharmacokinetic (PK) proﬁles of both the 3,4-DAP
free base and phosphate salt forms in this study were
highly variable, with up to 10-fold differences in Cmax,
AUC, and t½ between subjects. The most probable
explanation for this variability appears to be the single
metabolic disposition of 3,4-DAP via the activity of
N-acetyl transferases (NATs) to form a single major
3-N-acetyl metabolite, which is inactive.12 NAT enzymes
are highly polymorphic in humans and vary consider-
ably with ethnicity. Phenotypically, a patient’s NAT
status can be classiﬁed, through a range of acetylation
activities, from slow to rapid. Variations of polymorphic
NAT corresponding with fast and slow acetylator
phenotypes have been found to signiﬁcantly affect the
PK and tolerability proﬁles of amifampridine.12
Understanding the PK properties of amifampridine
is particularly important because amifampridine has a1556narrow therapeutic index, and supratherapeutic expo-
sure has been associated with an increase in the risk for
seizures.2 The purpose of this study was to evaluate the
effects of food on the PK properties and relative
bioavailability of amifampridine phosphate salt.
SUBJECTS AND METHODS
Subjects
This study enrolled healthy subjects, both men and
women, aged 18 to 65 years and with a body mass index
between 18.5 and 30 kg/m2, inclusive. Subjects under-
went screening to conﬁrm eligibility within 28 days before
the administration of the ﬁrst dose of study drug.
Screening included physical examination, clinical labora-
tory evaluations (hematology, chemistry, and urinalysis),
and ECG. Women of childbearing potential must have
had a negative pregnancy test at screening. Sexually active
subjects of childbearing potential must have been willing
to use 2 acceptable methods of contraception while
participating in the study, with 1 method spermicidal.
Subjects were excluded if they could not tolerate
the study-speciﬁc diet or were breast-feeding. Subjects
were also excluded if they had received any prescribed
systemic or topical medication; nonprescribed sys-
temic or topical medication (including herbal rem-
edies, but excluding vitamin/mineral supplements);
any medication (including St. John’s wort or other
herbal remedy) known to chronically alter drug
absorption or elimination processes; medication that
prolongs the QT interval or QT interval corrected for
heart rate; alcohol, caffeine, poppy seed, or grapefruit
containing products; or amifampridine (base or phos-
phate salt) or fampridine (4-aminopyridine) within
deﬁned time periods before planned administration of
the ﬁrst dose of study drug.
Other exclusion criteria included a variety of signiﬁ-
cant diseases, disorders, or illnesses; high or low blood
pressure; ECG abnormalities; a history of cardiac
disease; and current or history of alcohol abuse, drug
abuse, or smoking within deﬁned time periods before
planned administration of the ﬁrst dose of study drug.
Study Design
This was a randomized (1:1), open-labeled,
2-treatment, 2-period crossover study to assess the
tolerability and effect of food on the relative bioavail-
ability of amifampridine phosphate salt in healthy
subjects after single-dose administration. Written in-
formed consent was obtained from each subject beforeVolume 37 Number 7
P.E. Haroldsen et al.any study-related activities were conducted. The study
protocol was approved by the institutional review
board (Reading Independent Ethics Committee). The
study was conducted in accordance with the sections
of the US Code of Federal Regulations relating to
clinical research studies and/or other national and local
regulations, including the Good Clinical Practice
guideline and the ethical principles established by the
Declaration of Helsinki (2000).
Each subject was randomly assigned to a treatment
period (interval) and treatment sequence (AB or BA)
and received 2 single doses of amifampridine phos-
phate salt. Treatment A was a single dose of amifam-
pridine phosphate salt consisting of 2 tablets (10 mg
of active pharmaceutical ingredient [API] in each
tablet, for a total dose of 20 mg API) administered
orally in a fasting state. The fasting state was estab-
lished using an overnight fast of Z10 hours. Treat-
ment B was a single dose of amifampridine phosphate
salt consisting of 2 tablets (20 mg total API) admin-
istered orally in a fed state. Subjects fasted overnight
forZ10 hours and then received a high-fat (60% of
total caloric content), high-calorie (800–1000 kcal)
test meal 30 minutes before dosing. A washout period
of 6 to 10 days separated the 2 dose administrations.
Blood and Urine Sampling
Blood and urine samples were collected at speciﬁc
times during the study for the measurement of plasma
and urinary concentrations of amifampridine and its
major metabolite, 3-N-acetyl amifampridine.
Blood samples for PK analyses were taken at 90  5
minutes before and at 10, 15, 30, 45, 60, 75 minutes
and 1.5, 2, 4, 6, 8, 10, 12, 18, and 24 hours after dose
administration. Blood samples were collected into lith-
ium heparin tubes (Vacutainer; Becton, Dickinson and
Company, Franklin Lakes, New Jersey) and, after
mixing, were placed into a cool box containing crushed
ice/water. Blood samples were centrifuged within 1 hour
of collection, and 1 mL of the separated plasma was
transferred into 2 prechilled polypropylene tubes within
2 hours of collection and subsequently stored at
701C until quantiﬁcation by LC-MS/MS analysis.
Sample processing and storage was completed in com-
pliance with Good Laboratory Practice standards.
Urine samples were collected at r90 minutes before
dose administration (single sample) and at 0 to 4, 4 to 8,
and 8 to 24 hours after dose administration to quantify
total dose excreted as nonmetabolized amifampridine orJuly 20153-N-acetyl amifampridine. During each collection period,
the containers were stored in a refrigerator at 21C to 81C.
The weight of each urine sample was recorded before the
removal of 2 subsamples, which were stored, within 4
hours of the end of the collection, at approximately
701C. The remaining urine was discarded.
Analytical Methods
Plasma and urinary concentrations of amifampri-
dine and 3-N-acetyl amifampridine were determined
using acetonitrile precipitation extraction followed by
HPLC-MS/MS detection (SGS Bioanalytical Services,
Cephac, Saint-Benoit, France).
Brieﬂy, 25 mL of plasma sample was mixed with
300 mL of acetonitrile containing the internal stand-
ards and 0.1% formic acid. After vortex-mixing and
centrifugation, 300 mL of supernatant was transferred
to a clean 96-well plate, and a portion of this amount
was directly injected into the LC-MS/MS system. For
urine quantiﬁcation, a 20-mL sample was mixed with
1.2 mL of acetonitrile containing 0.1% formic acid
and internal standards. After vortex-mixing and cen-
trifugation, 300 mL of supernatant was transferred to
a clean 96-well plate, and a portion of this amount
was directly injected into the LC-MS/MS system. The
method employed individual stable isotope-labeled
internal standards for amifampridine ([2H3]-3,4-DAP)
and 3-N-acetyl amifampridine ([2H3]-3-N-acetyl). The
HPLC system consisted of two 20-AD pumps (Shi-
madzu Corporation, Tokyo, Japan) operated in a
high-organic (acetonitrile) to high-aqueous (0.1%
formic acid in water) gradient ﬂow at 0.8 mL/min
with a Waters Atlantis HILIC silica column (3 
100 mm, 3-mm particle size; Waters Corporation,
Milford, Massachusetts) held at 451C. A portion of
the eluent (0.3 mL) was transferred directly to an
API 3000 mass spectrometer (AB Sciex, Foster City,
California) operated in a positive ESI mode with
tandem quadrupole mass ﬁltering. The settings for
monitoring each analyte consisted of a characteristic
protonated precursor ion (M þ Hþ) to product ion
mass transition, as follows: amifampridine, 110- 93
Da; 2H3-amifampridine, 113 - 96 Da; 3-N-acetyl
amifampridine, 152 - 110 Da; and 3-N-2H3-acetyl
amifampridine, 155 - 111 Da. Each precursor–
product ion transition was optimized to a particular
collision energy (27–30 eV) in the quadrupole colli-
sion cell, using nitrogen as the collision gas. In human
plasma, the lower limits of quantiﬁcation (LLOQs) of1557
Clinical Therapeuticsamifampridine and the metabolite were 0.5 and 2 ng/mL,
respectively. In urine, the LLOQs of both amifampri-
dine and the metabolite were 150 ng/mL.
Concentration results were calculated using a linear
calibration curve of drug-to-internal standard or
metabolite-to-internal standard peak area ratios and
calibration curves were generated using 1/X2-weighted
linear least squares (LS) regression. The assay perform-
ance was monitored daily with quality-control (QC)
samples using blank plasma or urine samples spiked
with reference standards as follows for amifampridine in
plasma: low QC, 1.0 ng/mL (mean accuracy, 97.2%
[N ¼ 34]; range, 89.5%–109% nominal); mid QC,
75 ng/mL (mean accuracy, 103% [N ¼ 32]; range,
94.8%–109% nominal); and high QC, 350 ng/mL
(mean accuracy, 98.9% [N ¼ 34]; range, 87.4%–
108% nominal); for amifampridine in urine: low QC,
300 ng/mL (mean accuracy, 109% [N ¼ 10]; range,
101%–119% nominal); mid QC, 6000 ng/mL (mean
accuracy, 105% [N ¼ 10]; range, 105%–112% nom-
inal); and high QC, 12,000 ng/mL (mean accuracy,
103% [N ¼ 10]; range, 89.2%–111%), and for 3-N-
acetyl amifampridine metabolite in plasma: low QC, 6
ng/mL (mean accuracy, 98.7% [N ¼ 32]; range,
87.6%–105% nominal); mid QC, 100 ng/mL (mean
accuracy, 96.8% [N ¼ 31]; range, 90.4%–100%
nominal); and high QC, 1500 ng/mL (mean accuracy,
96.0% [N ¼ 33]; range, 92.6%–97.3% nominal), for 3-
N-acetyl amifampridine metabolite in urine: low QC,
300 ng/mL (mean accuracy, 109% [N ¼ 12]; range,
98.3%–121% nominal); mid QC, 6000 ng/mL (mean
accuracy, 103% [N ¼ 12]; range, 90.5%–110% nom-
inal); and high QC, 12,000 ng/mL (mean accuracy,
103% [N ¼ 11]; range, 90.0%–109% nominal).
Tolerability Assessment
Tolerability was assessed throughout the study and
determined from the evaluation of adverse events
(AEs), clinical laboratory assessments (hematology,
chemistry, and urinalysis), physical examination
including vital sign assessments, 12-lead ECG, and
concurrent medication use. All AEs were assessed and
coded by the investigator using the Medical Dic-
tionary for Regulatory Activities version 13.1 (North-
rop Grumman Corporation, Falls Church, Virginia).
Pharmacokinetic Analysis
The PK population consisted of all subjects who
received at least 1 dose of study drug and had evaluable1558PK data. The PK analysis was conducted using Win-
Nonlin Enterprise version 5.2 (Pharsight Corporation,
Mountain View, California). PK parameter values were
determined using noncompartmental analysis. The
total amount of amifampridine or 3-N-acetyl DAP
metabolite drug equivalent excretion into 24-hour
urine collections was calculated. The total amount of
parent drug or 3-N-acetyl amifampridine metabolite
excreted into the urine was calculated by multiplying
total urine volume gathered during a collection interval
by the concentration of amifampridine quantiﬁed dur-
ing that collection interval (0–4, 4–8, or 8–24 hours).
To determine the total amount of drug or metabolite
excreted into urine in the full 24-hour collection period,
the 3 collection intervals from 0 to 24 hours were
separately summed together for each component. For
the conversion of metabolite to amifampridine equiv-
alents (due to a mass increase of 42 Da via acetylation),
the total mass of the 3-N-acetyl metabolite excreted in
a given interval was multiplied by a conversion factor
of 0.722 (109.1/151.1).
Statistical Analysis
AUC0–1, AUC0–t, and Cmax were subject to stat-
istical analysis by fed/fasted status. These PK param-
eter values were logarithm-transformed (base e) before
analysis and were analyzed using a mixed model. The
model included sequence, period, and treatment as
ﬁxed effects and subject as a random effect. For these
parameters, LS means and mean differences were
calculated for the fed and fasted states. The residual
variance from the mixed model was used for calculat-
ing the 90% CI of the difference between the fed and
fasted states. These values were back-transformed to
give geometric LS means, a point estimate, and 90%
CI of the ratio of the fed relative to the fasted
treatment. A food effect on bioavailability was estab-
lished if the 90% CI of the ratio of population
geometric mean AUC0–1, AUC0–t, or Cmax value
between the fed and fasted states was not contained
within the bioequivalence range of 80% to 125%.
RESULTS
Subjects
A total of 47 subjects took part in this study. One
subject was withdrawn from the study due to a positive
cotinine test result at check-in for the fed period of the
study and was not included in the analysis of the fed
state. Two subjects were not included in the fastedVolume 37 Number 7
P.E. Haroldsen et al.group; 1 subject was withdrawn from the study due to a
severe AE of gastroenteritis during the fed portion of the
study (described subsequently), and the other subject
was withdrawn from the study due to a positive cotinine
test result at check-in for the fasted period of the study.
The mean age of the subjects was 37 years; mean body
mass index, 24.6 kg/m2. The study population was
predominately male, white, and non-Hispanic. The
overall summary statistics for the baseline demographic
characteristics are presented in Table I.Pharmacokinetic Properties of Amifampridine
and the Inactive 3-N-Acetyl Amifampridine
Metabolite under Fasting and Fed Conditions
Single oral dose administration of amifampridine
phosphate salt tablets (2 tablets, 20 mg total API) with
a high-fat meal was associated with a decrease in
systemic exposure (Cmax, AUC) to amifampridineTable I. Baseline demographic and clinical
characteristics of the subjects in this
study of the effects of food intake on
the relative bioavailability of
amifampridine 20 mg (N ¼ 47).*
Characteristic Value
Age, y
Mean (SD) 37 (13.4)
Range 19–62
Sex, no. (%)
Male 31 (66.0)
Female 16 (34.0)
Race, no. (%)
White 41 (87)
Black 3 (6)
Other 3 (6)
Weight, kg
Mean (SD) 72.5 (11.78)
Range 49.5–98.5
Height, cm
Mean (SD) 171 (9.9)
Range 140–189
Body mass index, kg/m2
Mean (SD) 24.6 (2.60)
Range 19.4–29.5
*All patients were of non-Hispanic ethnicity.
July 2015compared with administration in the fasted state
(Table II and Figure). The mean Tmax was longer
under fed conditions, indicating that food decreases the
rate of amifampridine absorption. The mean terminal t½
of amifampridine was not substantially altered by food.
The extent of exposure based on geometric mean
ratios (fed-to-fasted) suggests that the administration
of amifampridine under fed conditions resulted in a
decrease in absorption, with an 18% to 20%
decrease in overall exposure (AUC) and a 44%
decrease in Cmax in the presence of food compared
with those in fasted conditions (Table II). Geometric
LS mean ratios (point estimates) with 90% CIs for
bioequivalence bounds of 80% to 125% suggested a
signiﬁcant food effect on Cmax because the CI
(47.0%–67.5%) was not contained within the
bioequivalence limits. However, for AUC0–t and
AUC0–1, the CIs overlapped the bioequivalence
range; the upper limits of the CIs were contained
within, whereas the lower limits of the CIs were
outside the bioequivalence range (73.1%–87.6% and
76.0%–89.2%, respectively). By this strict criterion of
CI limits, the AUC exposures were not signiﬁcantly
different between the fed and fasted states. The results
from the linear mixed-effects model suggest a lack of
sequence and period effects (P4 0.1) of the crossover
treatment design. A carryover effect was also absent in
the study due to amifampridine levels below the
LLOQ before dosing in treatment period 1 (drug
naïve) and treatment period 2 (with a washout
interval of 6–8 days between treatment periods 1
and 2).
Intersubject variability in amifampridine PK expo-
sure (Cmax and AUCs) was high. PK parameter values
ranged broadly across subjects, from 8- to 45-fold for
AUC0–t under fed (8.3–282 ng  h/mL) and fasted
(20.6–267 ng  h/mL) conditions, AUC0–1 under fed
(9.66–292 ng  h/mL) and fasted (22.1–271 ng 
h/mL) conditions, and Cmax under fed (2.81–132
ng/mL) and fasted (16.0–137 ng/mL) conditions. For
the terminal t½, the ranges across subjects varied from
3.5- to 4.5-fold under fed (0.82–3.78 hours) and
fasted (1.23–4.31 hours) conditions.
Mean (SD) AUC0–t values were numerically higher
in women than in men under fed (120 [98.3] vs
94.6 [58.8] ng  h/mL) and fasted (129 [93.4] vs
104 [62.7] ng  h/mL) conditions. However, the
variability in these values was sufﬁciently high
(%CVs, 63%–88%) that the differences were most likely1559
Table II. Effects of food intake on the pharmacokinetic properties and urinary excretion of amifampridine and
3-N-acetyl amifampridine metabolite with the administration of amifampridine 20 mg in healthy
subjects. Data are given as mean (SD).
Parameter Fed (n ¼ 46) Fasted (n ¼ 45)
Amifampridine
AUC0–t, ng  h/mL* 103 (74.8) 113 (75.0)
AUC0–1, ng  h/mL† 109 (76.4) 117 (76.6)
Cmax, ng/mL
‡ 40.6 (31.3) 59.1 (34.4)
Tmax, h 1.31 (0.88) 0.637 (0.247)
t½, h 2.28 (0.704) 2.50 (0.730)
3-N-acetyl amifampridine metabolite
AUC0–t, ng  h/mL* 1193 (350) 1415 (372)
AUC0–1, ng  h/mL† 1220 (355) 1444 (378)
Cmax, ng/mL 189 (79.3) 268 (93.4)
Tmax, h 2.12 (1.14) 1.27 (0.348)
t½, h 4.03 (0.646) 4.10 (0.682)
Geometric mean ratios (90% CI), based on analysis of natural logarithm–transformed data.
*80.0 (73.1–87.6).
†82.3 (76.0–89.2).
‡56.3 (47.0–67.5).
Clinical Therapeuticsnot signiﬁcant. Differences in mean Cmax values
between women and men were small in both the fed
(41.5 [36.6] vs 40.1 [28.7] ng/mL, respectively) and
fasted (59.0 [37.3] vs 59.1 [33.4] ng/mL) conditions.
Amifampridine is metabolized by NAT to form a
single major 3-N-acetyl metabolite, which is inac-
tive.12 As with amifampridine PK under fed condi-
tions, a decrease in systemic exposure (AUC, Cmax) to
the 3-N-acetyl metabolite was observed, with a corres-
ponding longer mean Tmax under fed conditions,
indicating that the food effect decreased the rate of
amifampridine absorption and consequently the rate
of 3-N-acetyl metabolite formation (Table II and
Figure). The 3-N-acetyl plasma amifampridine
metabolite concentrations were greater than amifam-
pridine concentrations in all subjects at all time points
(Table II). The resulting plasma PK exposure para-
meter measurements were greater than amifampridine
AUC0–1 and Cmax under fed (11.2- and 4.66-fold)
and fasting (12.3- and 4.53-fold) conditions. The
mean terminal t½ of the 3-N-acetyl metabolite was
also longer than the t½ for amifampridine under fed
(4.03 vs 2.28 hours) and fasted (4.10 vs 2.50 hours)
conditions. The mean metabolite exposure indexes1560(based on ratios of metabolite to parent drug) were
greater for the PK exposure parameters Cmax and
AUC in both the fasted and fed conditions (AUC0–t:
fed, 11.6; fasted, 12.5; AUC0–1: fed, 11.2; fasted,
12.3; and Cmax: fed, 4.66; fasted, 4.53).
PK exposure ranges of the 3-N-acetyl amifampri-
dine metabolite across subjects varied widely and were
less under fed conditions (AUC0–t: fed, 703–2364 ng 
h/mL; fasted, 816–2534 ng  h/mL; AUC0–1: fed,
715–2408 ng  h/mL; fasted, 83–2595 ng  h/mL; and
Cmax: fed, 90.1–406 ng/mL; fasted, 119–609 ng/mL).
Nearly all (493%) of the administered dose of
amifampridine phosphate salt was renally eliminated
as either unchanged amifampridine or the 3-N-acetyl
metabolite within 24 hours (Table III). The fraction of
unchanged amifampridine eliminated in the 0 to 24
hour urine collections averaged 18.8% (fasted) to
19.2% (fed) of the administered dose, whereas the
3-N-acetyl metabolite represented 74.0% (fed) to
81.7% (fasted) of the administered dose.
Tolerability
The prevalences of AEs (ie, numbers of subjects with
Z1 AE) were similar between the fed (23/46 [50%])Volume 37 Number 7
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Figure. Effects of food intake on mean (SD) plasma concentrations of amifampridine (A), inset from 0–6 hours
emphasizes the shift in time to maximal concentration and differences in the rate of absorption and
3-N-acetyl amifampridine metabolite (B) over time after the administration of amifampridine 20 mg.
P.E. Haroldsen et al.and fasted (24/45 [53%]) states, although the fre-
quency of AEs (ie, total number of AEs) was less in the
fed state (40 AEs) compared with that in the fasted
state (61 AEs). The most frequent AEs (50% of all
AEs) were paresthesias (paresthesia and oral paresthe-
sia), which are well-known adverse effects of amifam-
pridine treatment. In both the fed and fasted states, the
majority of AEs reported were mild and resolved
without treatment. One severe AE of gastroenteritis,
which was not considered by the investigator to be
related to the study drug, was associated with subject
withdrawal from the study. There were no deaths,
serious AEs, or clinically meaningful ﬁndings fromJuly 2015clinical laboratory evaluations, 12-lead ECGs, or
physical examinations including vital sign assessments.
DISCUSSION
Overall in this study, there was a decrease in amifam-
pridine exposure (44% in Cmax and 20% in AUCs)
after oral administration of amifampridine phosphate
salt in the presence of food. Mean Tmax was longer in
the fed state (1.31 hours) than in the fasted state
(0.637 hour). The delay in Tmax may have been
attributable to differences in gastric emptying time in
the presence of food that delayed the introduction of
drug to the duodenum for absorption. Together, these1561
Table III. Effects of food intake on urinary
excretion of amifampridine and 3-N-
acetyl amifampridine metabolite with
the administration of amifampridine
20 mg in healthy subjects. Data are
given as % of total dose excreted in
urine.
Parameter
Fed
(n ¼ 46)
Fasted
(n ¼ 45)
Amifampridine
Mean (SD) 19.2 (12.8) 18.8 (11.8)
Range 0.940–42.2 2.34–36.3
3-N-acetyl amifampridine metabolite
Mean (SD) 74.0 (18.3) 81.7 (15.3)
Range 26.9–104 42.7–122
Total (amifampridine þ 3-N-acetyl amifampridine
metabolite)
Mean (SD) 93.2 (12.4) 100 (11.7)
Range 54.6–121 69.8–126
Clinical Therapeuticsﬁndings suggest that food slows and somewhat de-
creases the absorption of amifampridine.
This was the ﬁrst in-human study to identify and
quantify the major metabolite 3-N-acetyl-amifampri-
dine. In comparison with the parent compound,
metabolite levels were greater in all subjects and at
all time points, whether fed or fasted. In both the fed
and fasted states, Cmax and AUC values of the 3-N-
acetyl amifampridine metabolite were 4.5-fold and
12-fold greater than those of amifampridine. The
mean plasma elimination t½ of the 3-N-acetyl metabo-
lite was longer than that of amifampridine, in both the
fed (4.03 vs 2.28 hours) and fasted (4.10 vs
2.50 hours) states. Thus, the duration and extent of
exposure to the inactive metabolite were greater than
those of the parent compound.
The mean AUCs in the fed and fasted states were
slightly greater in women than in men, with no
difference in mean Cmax values. Due to the high level
of variability observed in these PK values, it is not
clear whether the sex differences are signiﬁcant.
Orally administered amifampridine phosphate salt
appears to undergo rapid renal elimination, with
493% excretion from the body within 24 hours as
either the parent drug or the metabolite.
A high intersubject variability in amifampridine PK
parameter values was observed in this study. The most1562probable explanation for the high variability is the
metabolic disposition of amifampridine through a single
pathway via NAT enzymes 1 and 2. NAT-1 and NAT-2
are known to be highly polymorphic in humans, with
recognized slow, intermediate, and fast acetylator pheno-
types. Slow and fast acetylator NAT phenotypes affect
the overall PK and disposition of amifampridine, with
slow acetylator phenotypes producing less 3-N-acetyla-
mifampridine metabolite and being associated with
480% more AEs than fast acetylator phenotypes.12 In
the present study involving a mixture of undifferentiated
NAT phenotypes, the %CVs of Cmax and AUC were
60% to 70%, and the PK parameter values in subjects
varied over a range of 410-fold.
Single oral doses of amifampridine phosphate salt
(20 mg API) were considered to be well tolerated
when administered in healthy male and female
subjects in both the fed and fasted conditions.
Amifampridine has a narrow therapeutic index in
which a relatively small increase in exposure at the
intended dose (20 mg) can increase the risk for seizure.2
The potentials for higher exposure and overdose are
increased in subjects who display slow acetylator
phenotypes,12 and/or who are taking amifampridine
under fasting conditions. Thus, with subjects of
unknown slow acetylator phenotype in a fasted state
taking a compounded form of 3,4-DAP of unknown
strength, a “perfect storm” could result, in which
unintended maximal exposures are achieved. Adverse
effects observed with amifampridine dosing appear to
be related to a greater Cmax in those with slow acetylator
phenotypes.12 Based on the ﬁndings presented herein,
amifampridine exposures are moderated when
amifampridine is taken with food and are maximized
when amifampridine is taken in a fasted state. Therefore,
in the absence of individual acetylator status information,
amifampridine phosphate salt tablets should be taken
with or without food in a consistent manner to avoid
inadvertent variable exposure, and on the initiation of
treatment, the dose should be increased gradually to
determine a well-tolerated and effective level. If the
desired effect is not observed, dosing in the fed or fasted
state may be changed slowly to ensure well-tolerated
dosing up to an effective level.CONCLUSIONS
In this randomized, open-labeled, crossover trial in
healthy male and female subjects, the ingestion ofVolume 37 Number 7
P.E. Haroldsen et al.amifampridine phosphate salt with a high-fat meal
was associated with a decrease in exposure, based on
mean Cmax (44%) and AUC (20%) and an approx-
imate 2-fold decrease in absorption rate based on
Tmax, compared with the fasting state. The major
amifampridine metabolite, 3-N-acetyl-amifampridine,
was identiﬁed and quantiﬁed in this study for the ﬁrst
time in humans. Plasma concentrations of the metab-
olite were observed to have been greater than those of
amifampridine in all subjects at all time points in both
the fed and fasted states. The results from this study
and from a previous Phase I PK study suggest that
amifampridine phosphate salt PK properties can be
affected by both a subject’s acetylation status and
whether the drug is administered under fed or fasted
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